Dry Eye Disease Affects Around 50M Americans, OKYO Pharma's Candidate Shows Safety In Mid-Stage Study
Portfolio Pulse from Vandana Singh
OKYO Pharma Limited's drug candidate, OK-101, currently in a phase 2 trial for dry eye disease (DED), is showing a positive safety profile. The trial involves 240 patients, with 95% having completed four weeks of dosing. The company expects the last patient's last visit to occur in November 2023, with top-line data to be released in December 2023. DED affects approximately 49 million people in the US. OKYO shares are down 17.60% at $2.29.
October 05, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
OKYO Pharma's drug candidate, OK-101, is showing a positive safety profile in its phase 2 trial for dry eye disease. Despite this, OKYO shares are down 17.60%.
Despite the positive news about OKYO Pharma's drug candidate, OK-101, the company's shares are down. This could be due to a variety of factors, including market conditions or investor sentiment. However, the successful development of OK-101 could potentially have a positive impact on the company's stock in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100